Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Helicobacter Pylori Diagnostics Market is projected to expand from USD 605.78 Million in 2025 to USD 780.32 Million by 2031, registering a Compound Annual Growth Rate (CAGR) of 4.31%. This sector encompasses a range of invasive and non-invasive diagnostic tools, including urea breath tests, stool antigen assays, and endoscopic biopsies, which are essential for detecting bacterial colonization in the gastric mucosa. The primary catalyst for market growth is the high global prevalence of peptic ulcers and the urgent necessity to lower gastric cancer risks through early pathogen identification. As reported by the American College of Gastroenterology in 2024, Helicobacter pylori infection rates in North America remain significant, fluctuating between 30% and 40%, highlighting a sustained clinical requirement for accurate diagnostic interventions.

One major hurdle impeding market expansion is the economic and logistical difficulty of implementing high-precision testing in developing nations. Although these regions suffer the heaviest infection burdens, the high cost of advanced non-invasive diagnostics and inadequate laboratory infrastructure often preclude widespread screening and surveillance efforts. This gap in accessibility limits market penetration in resource-poor settings, thereby constraining the overall revenue potential despite the existence of a vast patient population.

Market Drivers

The escalating incidence of H. pylori-associated peptic ulcers and gastric cancer acts as the primary engine for market growth. Since this pathogen is the strongest identifiable risk factor for non-cardia gastric cancer, clinical guidelines increasingly mandate eradication therapy, which relies heavily on accurate initial diagnosis to prevent malignancy. This direct correlation between long-term infection and oncology drives screening volumes, particularly in high-risk regions where early intervention is prioritized. The International Agency for Research on Cancer highlighted this urgency in February 2024, noting that stomach cancer accounted for approximately 970,000 new cases globally in 2022, underscoring the critical need for early bacterial detection to mitigate oncological risks.

Simultaneously, the diagnostic landscape is being transformed by a marked shift in preference from invasive biopsies to breath and stool antigen tests. Healthcare systems and patients increasingly favor non-invasive modalities due to their lower cost, ease of use, and reduced procedural discomfort compared to endoscopic methods. This trend is evident in the financial performance of major diagnostic manufacturers; for instance, Otsuka Holdings Co., Ltd. reported in February 2024 that its Medical Devices division generated 15.64 billion yen in sales for fiscal 2023, largely driven by urea breath test systems. Furthermore, Phathom Pharmaceuticals estimated in 2024 that there are 115 million infected individuals in the United States alone, representing a substantial addressable market for diagnostic utilization.

Market Challenges

Significant economic and logistical barriers to deploying high-precision testing in developing nations constitute a major impediment to the growth of the Global Helicobacter Pylori Diagnostics Market. While these regions exhibit the highest density of bacterial colonization, the substantial costs of non-invasive modalities render them financially inaccessible for widespread screening. This pricing disparity effectively excludes a vast segment of the potential patient pool from the addressable market, as healthcare systems in low-resource settings prioritize acute care over preventative surveillance. Consequently, diagnostic manufacturers face diminished revenue realization in geographies that hold the highest volume of latent demand.

Moreover, the deficiency in laboratory infrastructure severely limits the scalability of accurate detection methods. Many diagnostic protocols require specialized equipment that is often unavailable in underfunded medical centers, forcing reliance on empiric treatment and stalling the adoption of modern technologies. The magnitude of this missed opportunity is significant given the persistent disease burden; according to the American Gastroenterological Association in 2024, the global prevalence of Helicobacter pylori infection among children and adolescents persists at 35.1%. This statistic confirms a continuous reservoir of infection that current market strategies fail to reach due to these logistical barriers.

Market Trends

The rise of Antimicrobial Susceptibility Testing capabilities is fundamentally altering the clinical approach to Helicobacter pylori management, driven by the escalating failure rates of traditional empiric therapies. With global antibiotic resistance reaching critical levels, healthcare providers are increasingly prioritizing diagnostic tools that can identify specific bacterial resistance profiles, particularly for clarithromycin and metronidazole, prior to prescribing treatment. This transition from simple detection to detailed susceptibility profiling is essential to prevent the administration of ineffective regimens and to steward antibiotic use. According to the National Institutes of Health in December 2024, primary resistance rates among children were reported at 35.3% for metronidazole and 32.6% for clarithromycin, underscoring the urgent market demand for diagnostics that provide comprehensive resistance data.

Concurrently, a shift toward Personalized Precision Medicine Diagnostics is gaining traction, leveraging genotypic insights to tailor eradication strategies for individual patients. This trend moves the market beyond binary positive/negative results, encouraging the adoption of molecular assays that guide the selection of the most efficacious first-line therapies based on the patient's specific bacterial strain. By integrating genotypic resistance testing into routine care, clinicians can significantly improve treatment outcomes compared to standard trial-and-error methods. According to Digestive Disease Week in May 2025, the implementation of genotypic resistance testing to guide first-line therapy increased eradication success rates to 93%, compared to just 77% with empiric therapy, validating the clinical and commercial value of precision diagnostics.

Key Players Profiled in the Helicobacter Pylori Diagnostics Market

• Thermo Fisher Scientific inc.
• Biohit Oyj
• Quest Diagnostics Incorporated
• Meridian Bioscience
• Bio-Rad Laboratories
• Alpha Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Coris BioConcept
• Certest Biotec
• Epitope Diagnostics, Inc.

Report Scope

In this report, the Global Helicobacter Pylori Diagnostics Market has been segmented into the following categories:

Helicobacter Pylori Diagnostics Market, by Type:

• Instruments
• Reagents
• Services

Helicobacter Pylori Diagnostics Market, by Technology:

• Immunoassays
• POC
• Molecular Diagnostics

Helicobacter Pylori Diagnostics Market, by End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Helicobacter Pylori Diagnostics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Helicobacter Pylori Diagnostics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.